Open Medicine EU

Archives for Uncategorized

ZYPREXA OFF-LABEL

Prescribing “off-label” means prescribing a medicine for a use for which it is not authorised. Pharmaceutical companies may not promote off-label use of their medicines, for good reason. There is not the same tested scientific base for off-label use as there is for authorised use. Qualified doctors may prescribe off-label, on the basis of their… » read more

Posted by Jim Murray

Now, some changes, and clarifications, for the New Year. First a change of banner. A friend who knows about these things tells me that the original banner is “amateurish”. This is hard but may be true, because I designed it myself. (If anyone is interested, my design was supposed to represent the rising sun of… » read more

Posted by Jim Murray

New Study on False Claims

I was proud to be there at the beginning of the Transatlantic Consumer Dialogue (TACD) in 1998. It was and is the focus for a very fruitful collaboration between major EU and US consumer groups, in many fields including pharmaceuticals. One of the US partners in that collaboration, Public Citizen, has recently published the results… » read more

Posted by Jim Murray

The Limits of Psychiatry?

This post is a slight digression from the core themes of the blog but it does have some connection to medicine and science, or at least to how not to do it. I dislike reading in the media quotes from psychiatrists offering a quasi-diagnosis of living people whom they have never met. There was a… » read more

Posted by Jim Murray

How Dreadful

I’ve just read on the Fierce Pharma website that the FDA proposes to test a drug imported from the UK that is to be used in the execution of prisoners on death row in the U.S. I suppose there is a kind of grim logic in trying to ensure that the drug does not cause… » read more

Posted by Jim Murray

English laws on libel stifle scientific debate, not only in England but around the world. There are three problems: – English law is more favourable to the plaintiff than the laws in many other countries. – The costs of defending a libel action in London are very high – from 100 000 euros for starters… » read more

Posted by Jim Murray

As mentioned in my previous post, the European Medicines Agency has announced a new transparency policy. Not before time. -In an article in the BMJ in April this year the authors cited earlier research indicating that the EMA was very much less transparent that the FDA in a number of key areas, including information on… » read more

Posted by Jim Murray

The European Medicines Agency announced today (30th November) a new transparency policy that would widen access to documents held by the agency. This is good news (apart from the fact that I had to scrap a post I had just finished, attacking the old policy…) I believe that the agency will be more transparent under… » read more

Posted by Jim Murray

AstraZeneca on Transparency

Interesting report on FoxBusiness News ( I know, I know). The global pharmaceuticals industry must become more transparent if it is to rebuild public trust in the sector, AstraZeneca PLC’s chief executive said Wednesday. David Brennan told a gathering of drug sector leaders that industry stockholders need to collaborate to collectively address the world’s healthcare… » read more

Posted by Jim Murray